Osteosarcoma Journey in India: Each Step Reveals a New Horizon!

Abstract

Osteosarcoma remains one of the most challenging cancers of childhood and young adults wherein the addition of chemotherapy to surgery has led to dramatic but improvements in the event-free survival (EFS) (from 20% to 60%). However, these improvements have been largely reported in developed nations, with a gross mismatch seen in low-and middle-income countries (LMICs). However, even in high-income countries, the outcomes are largely static since the past three decades. [1] Osteosarcoma therapy protocols mainly utilize a dyad backbone of cisplatin and doxorubicin, with the addition of a third drug, either ifosfamide or high-dose methotrexate (HDMTX), which has led to rapid strides forward in survival in osteosarcoma. [1]

Resource‐appropriate selection of osteosarcoma treatment protocols in low‐ and middle‐income countries

“…Identifying the impediments to better outcomes and the remedial measures will help bridge the gap between outcomes 7,8 . Sustainable care consisting of effective and practical treatment protocols designed in the LMIC are highly relevant in improving survival outcomes economically 9 …”